290 related articles for article (PubMed ID: 24928989)
1. CD40 ligand preferentially modulates immune response and enhances protection against influenza virus.
Hashem AM; Gravel C; Chen Z; Yi Y; Tocchi M; Jaentschke B; Fan X; Li C; Rosu-Myles M; Pereboev A; He R; Wang J; Li X
J Immunol; 2014 Jul; 193(2):722-34. PubMed ID: 24928989
[TBL] [Abstract][Full Text] [Related]
2. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
[TBL] [Abstract][Full Text] [Related]
3. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.
Fu TM; Guan L; Friedman A; Schofield TL; Ulmer JB; Liu MA; Donnelly JJ
J Immunol; 1999 Apr; 162(7):4163-70. PubMed ID: 10201942
[TBL] [Abstract][Full Text] [Related]
4. Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes.
Fan X; Hashem AM; Chen Z; Li C; Doyle T; Zhang Y; Yi Y; Farnsworth A; Xu K; Li Z; He R; Li X; Wang J
Mucosal Immunol; 2015 Jan; 8(1):211-20. PubMed ID: 25052763
[TBL] [Abstract][Full Text] [Related]
5. Influenza-induced, helper-independent CD8+ T cell responses use CD40 costimulation at the late phase of the primary response.
Seah SG; Brady JL; Carrington EM; Ng WC; Sutherland RM; Hancock MS; La Gruta NL; Brown LE; Turner SJ; Lew AM; Zhan Y
J Leukoc Biol; 2013 Jan; 93(1):145-54. PubMed ID: 23108101
[TBL] [Abstract][Full Text] [Related]
6. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein.
Tamura S; Miyata K; Matsuo K; Asanuma H; Takahashi H; Nakajima K; Suzuki Y; Aizawa C; Kurata T
J Immunol; 1996 May; 156(10):3892-900. PubMed ID: 8621928
[TBL] [Abstract][Full Text] [Related]
7. Anti-viral immunity induced by recombinant nucleoprotein of influenza A virus. II. Protection from influenza infection and mechanism of protection.
Tite JP; Hughes-Jenkins C; O'Callaghan D; Dougan G; Russell SM; Gao XM; Liew FY
Immunology; 1990 Oct; 71(2):202-7. PubMed ID: 2172156
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.
Liu Y; Zhang X; Zhang W; Chen Z; Chan T; Ali K; Jia Z; Xiang J
Cancer Gene Ther; 2002 Feb; 9(2):202-8. PubMed ID: 11857039
[TBL] [Abstract][Full Text] [Related]
9. Single mucosal vaccination targeting nucleoprotein provides broad protection against two lineages of influenza B virus.
Kim MH; Kang JO; Kim JY; Jung HE; Lee HK; Chang J
Antiviral Res; 2019 Mar; 163():19-28. PubMed ID: 30639307
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge.
Epstein SL; Stack A; Misplon JA; Lo CY; Mostowski H; Bennink J; Subbarao K
Int Immunol; 2000 Jan; 12(1):91-101. PubMed ID: 10607754
[TBL] [Abstract][Full Text] [Related]
11. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge.
Lawson CM; Bennink JR; Restifo NP; Yewdell JW; Murphy BR
J Virol; 1994 Jun; 68(6):3505-11. PubMed ID: 7514677
[TBL] [Abstract][Full Text] [Related]
12. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice.
Ninomiya A; Ogasawara K; Kajino K; Takada A; Kida H
Vaccine; 2002 Aug; 20(25-26):3123-9. PubMed ID: 12163263
[TBL] [Abstract][Full Text] [Related]
13. Vaccine molecules targeting Xcr1 on cross-presenting DCs induce protective CD8+ T-cell responses against influenza virus.
Fossum E; Grødeland G; Terhorst D; Tveita AA; Vikse E; Mjaaland S; Henri S; Malissen B; Bogen B
Eur J Immunol; 2015 Feb; 45(2):624-35. PubMed ID: 25410055
[TBL] [Abstract][Full Text] [Related]
14. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.
Tao P; Luo M; Pan R; Ling D; Zhou S; Tien P; Pan Z
Antiviral Res; 2009 Mar; 81(3):253-60. PubMed ID: 19135483
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of the influenza virus-specific CD4+ T cell memory in the absence of B cells and Ig.
Topham DJ; Tripp RA; Hamilton-Easton AM; Sarawar SR; Doherty PC
J Immunol; 1996 Oct; 157(7):2947-52. PubMed ID: 8816401
[TBL] [Abstract][Full Text] [Related]
16. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein.
Vignuzzi M; Gerbaud S; van der Werf S; Escriou N
J Gen Virol; 2001 Jul; 82(Pt 7):1737-1747. PubMed ID: 11413386
[TBL] [Abstract][Full Text] [Related]
17. CD154+ CD4+ T-cell dependence for effective memory influenza virus-specific CD8+ T-cell responses.
Olson MR; Seah SG; Edenborough K; Doherty PC; Lew AM; Turner SJ
Immunol Cell Biol; 2014 Aug; 92(7):605-11. PubMed ID: 24777309
[TBL] [Abstract][Full Text] [Related]
18. Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model.
Dhakal S; Loube J; Misplon JA; Lo CY; Creisher PS; Mulka KR; Deshpande S; Mitzner W; Klein SL; Epstein SL
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627390
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of protective immunity against influenza virus infection in mice without antibodies.
Epstein SL; Lo CY; Misplon JA; Bennink JR
J Immunol; 1998 Jan; 160(1):322-7. PubMed ID: 9551987
[TBL] [Abstract][Full Text] [Related]
20. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
